Product image of Levonance 20 (Ethinylestradiol, Levonorgestrel) supplied by GNH India

Levonance 20

Active Ingredient:
Ethinylestradiol, Levonorgestrel
Origin:
EU

Levonance 20 (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol / Levonorgestrel, the active ingredients in Levonance 20, are a combined oral contraceptive presented as a 20 µg/100 µg tablet for oral use. They work to prevent pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus and the endometrium.

GNH India supplies Levonance 20 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this EU‑approved hormonal contraceptive.

Manufacturer / TM Owner

Acis Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Levonance 20, a combined oral contraceptive, is used to prevent pregnancy by acting on the hormonal regulation of the menstrual cycle.
  • Contraception: provides reliable prevention of unintended pregnancy when taken as directed.
  • Family planning: supports planned childbearing by offering reversible oral birth control.
  • Hormonal contraception: offers a low‑dose estrogen‑progestin regimen for women seeking oral birth control.

How It Works

  • Ethinylestradiol and levonorgestrel bind to estrogen and progesterone receptors, respectively, suppressing the hypothalamic‑pituitary‑gonadal axis. This inhibition reduces the release of gonadotropins (FSH and LH), preventing follicular development and ovulation. In addition, the progestin component thickens cervical mucus and induces endometrial changes that reduce the likelihood of implantation.

Side Effects

Levonance 20 may cause a range of adverse reactions. Most are mild and transient.

Common Side Effects

  • Nausea: mild stomach upset, especially during the first cycles.
  • Headache: tension‑type or migraine‑like pain.
  • Breast tenderness: temporary swelling or discomfort.
  • Spotting between periods: light vaginal bleeding.

Serious or Rare Side Effects

  • Deep vein thrombosis: blood clot formation in the legs.
  • Pulmonary embolism: clot migration to the lungs.
  • Stroke or myocardial infarction: rare cardiovascular events.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Liver tumor: very rare hepatic adenoma.
  • Hyperbilirubinemia: unusual jaundice.

Precautions & Warnings

  • Before prescribing Levonance 20, clinicians should evaluate individual risk factors and counsel patients on safe use.
  • Contraindicated in pregnancy: product is category X and must not be used by pregnant women.
  • Avoid in smokers over 35: increased risk of cardiovascular events.
  • Screen for thromboembolic risk: assess history of clotting disorders.
  • Monitor blood pressure: may cause slight elevation.
  • Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Avoid Interactions

Levonance 20 can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Enzyme‑inducing anticonvulsants (e.g., carbamazepine): reduce hormone levels.
  • Rifampin: may markedly decrease contraceptive effectiveness.
  • Protease inhibitors (e.g., ritonavir): can increase hormone concentrations.
  • St. John’s wort: herbal inducer that lowers efficacy.

Moderate Interactions (Monitor Closely)

  • Tetracycline antibiotics: may slightly reduce contraceptive effect.
  • Fluconazole and other azole antifungals: can increase hormone levels.
  • Diuretics: may affect fluid balance and blood pressure.

Frequently Asked Questions

Levonance 20 is a combined oral contraceptive containing ethinyloestradiol and levonorgestrel. It is prescribed to prevent unintended pregnancy in women of reproductive age by inhibiting ovulation and creating cervical mucus and endometrial changes that reduce the chance of implantation.

Ethinyloestradiol acts as a synthetic estrogen, binding to estrogen receptors and suppressing the release of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary. This suppression prevents the development of a dominant follicle, thereby inhibiting ovulation.

The dosing regimen for Levonance 20 is determined by the prescribing clinician. Typically, the product is taken as a daily tablet following a 21‑day active‑pill schedule with a 7‑day placebo interval, but the exact plan must be individualized by a healthcare professional.

Levonance 20 is classified as pregnancy category X, meaning it must not be used by women who are pregnant or suspect they might be pregnant. It is also not recommended for breastfeeding mothers because hormonal contraceptives can affect milk production and infant exposure.

To order Levonance 20, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify institutional credentials, then provide pricing, availability, shipping details, and any required import documentation.

Levonance 20 offers a low‑dose estrogen (20 µg) combined with 100 µg levonorgestrel, providing effective contraception with a reduced estrogen‑related risk profile compared with higher‑dose pills. Its efficacy and safety are comparable to other second‑generation combined oral contraceptives, while the specific hormone balance may influence side‑effect tolerability.

Levonance 20 tablets should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Levonance 20 is taken orally, usually once daily at the same time each day. The typical regimen consists of 21 consecutive active tablets followed by a 7‑day tablet‑free interval, during which withdrawal bleeding occurs.

The most serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, and severe allergic reactions. These events are rare but require immediate medical attention if symptoms such as sudden chest pain, shortness of breath, severe headache, or swelling of the limbs occur.

Women who are pregnant, have a known or suspected pregnancy, are breastfeeding, have a history of thromboembolic disorders, uncontrolled hypertension, certain cancers (e.g., estrogen‑dependent tumors), or who smoke cigarettes and are over 35 years old should avoid using Levonance 20.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT